SpyGlass Pharma Inc (SGP)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$28.94-0.17%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · SGP
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
A comparable price-assumption read is not available for this company.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
No outside relationship met the current evidence threshold.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Elevated risk of a next-quarter earnings miss: this name has been missing across recent quarters and operates in a high-miss-rate industry. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
SGP — earnings miss
Dated 2026-08-06
and in the accompanying Exhibit 99.1 shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
Why it matters: Watching cash burn will show how SpyGlass handles money after its IPO.
Worry ifCash burn exceeds $15 million in the next quarter, indicating financial strain.
Less concerning ifCash burn is under $15 million, which shows good money management.
Why it matters: This report will show if the company can improve from its recent earnings miss. Investors will look for signs of better performance.
Watch forQ2 earnings report shows revenue growth above 10% year over year.
Also watch forQ2 earnings report shows another earnings miss or negative revenue growth.
Why it matters: Starting this trial is crucial for expanding SpyGlass's product pipeline. It indicates progress in new treatments.
Supportive ifThe first-in-human trial of BIM-DRS starts in the second half of 2026.
Worry ifThe trial does not start as planned in the second half of 2026.
Why it matters: High cash burn could harm operations and slow down product development.
Worry ifOperating costs are higher than the expected burn rate of $15.4 million each quarter.
Less concerning ifOperating costs are in the expected range. This supports planned funding until 2028.
We watch for confirming and disproving signals on each item. Resolutions are found automatically where possible and checked by hand for unclear cases. Last 90 days shown.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$191 on $10,000 · ±1.9% | How much price usually moves either way. |
| Bad day | $695 loss on $10,000 · 7.0% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $4,084 loss on $10,000 · 40.8% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: A drop in sector revenue growth could impact SpyGlass Pharma's performance. It indicates a weakening market.
Worry ifSector revenue growth reported below its median for the latest quarter.
Less concerning ifSector revenue growth remains at or above its median for the latest quarter.
Why it matters: The health care sector is maturing, and revenue growth is slowing. A rebound could signal better conditions for SpyGlass Pharma.
Supportive ifHealth care sector revenue growth speeds up to 12% year over year.
Worry ifSector revenue growth keeps slowing down to below 6% year over year.
Why it matters: This data shows how well the BIM-IOL System works over time.
Supportive ifSafety and effectiveness data will come out in Q4 2026.
Worry ifThe presentation of the four-year data is postponed or does not occur.
Why it matters: Having enough cash is key for operations and trials. It affects financial health.
Worry ifCash and short-term investments remain above $200 million.
Less concerning ifCash reserves fall below $200 million. This raises worries about funding.
Why it matters: Continued high cash burn may raise concerns about funding operations through 2028.
Worry ifManagement states cash burn remains at or above $15.4M in Q2.
Less concerning ifManagement says cash burn is now below $15.4M in Q2.
Why it matters: New data could strengthen the case for the BIM-IOL System and attract investor interest.
Supportive ifSpyGlass announces a date for presenting additional results from the Phase 1/2 trial.
Worry ifNo news has come out about the presentation of more trial results.
Why it matters: Finishing enrollment is important for FDA approval. It shows progress in clinical trials.
Supportive ifEnrollment in the Phase 3 trials completes by the end of 2027 as planned.
Worry ifEnrollment completion is delayed beyond 2027.
Why it matters: Having enough cash is vital for operations and development. It helps keep things stable.
Worry ifCash and short-term investments are over $200 million. This is enough to fund operations until 2028.
Less concerning ifCash and short-term investments fall below $200 million. This raises concerns about funding.
Why it matters: A clear reimbursement pathway can boost adoption of the BIM-IOL System. It impacts future revenue potential.
Supportive ifThe new CPT code helps more surgeons use the system. It gets good feedback from doctors.
Worry ifSurgeon engagement is still low. Adoption of the BIM-IOL System is not improving.